PCSA.US Processa Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
1.72 USD
Close of Nov 16, 2026
1.04 8.88
Market cap
USD 4.81M
P/E
-
P/B
2.81x
ROE
-140.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PCSA.US undervalued?

Graham number

The Graham number of Processa Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Processa Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Processa Pharmaceuticals Inc yet.

Processa Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Processa Pharmaceuticals Inc

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 …

Full company profile